Finance
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
Erasca Inc. shares plunged as much as 55% Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.
B
Bloomberg
April 28, 2026·1 min read
Image: Bloomberg
Erasca Inc. shares plunged as much as 55% Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.
Original article
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
Published by Bloomberg